Nivolumab (new indication: oesophageal or gastro-oesophageal junction cancer, pretreated patients, adjuvant)

Subject:

• Active Substance: Nivolumab
• Name: Opdivo^®
• Therapeutic area: Oesophageal or gastro-oesophageal junction cancer
• Pharmaceutical company: Bristol Myers-Squibb GmbH & Co. KGaA

Time table:

• Start: 01.09.2021
• Final decision by G-BA: 17.02.2022
• This decision remains valid until: 01.10.2024

Final decision:

• Indication for a non-quantifiable additional benefit